JP2004516038A5 - - Google Patents

Download PDF

Info

Publication number
JP2004516038A5
JP2004516038A5 JP2002553118A JP2002553118A JP2004516038A5 JP 2004516038 A5 JP2004516038 A5 JP 2004516038A5 JP 2002553118 A JP2002553118 A JP 2002553118A JP 2002553118 A JP2002553118 A JP 2002553118A JP 2004516038 A5 JP2004516038 A5 JP 2004516038A5
Authority
JP
Japan
Prior art keywords
group
protein
arl4
dad1
chronic inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002553118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/014838 external-priority patent/WO2002052270A2/en
Publication of JP2004516038A publication Critical patent/JP2004516038A/ja
Publication of JP2004516038A5 publication Critical patent/JP2004516038A5/ja
Pending legal-status Critical Current

Links

JP2002553118A 2000-12-22 2001-12-15 慢性炎症性気道疾患の炎症性状態に陽性の影響を与える物質を同定するための方法 Pending JP2004516038A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25787800P 2000-12-22 2000-12-22
PCT/EP2001/014838 WO2002052270A2 (en) 2000-12-22 2001-12-15 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Publications (2)

Publication Number Publication Date
JP2004516038A JP2004516038A (ja) 2004-06-03
JP2004516038A5 true JP2004516038A5 (https=) 2005-04-21

Family

ID=22978162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002553118A Pending JP2004516038A (ja) 2000-12-22 2001-12-15 慢性炎症性気道疾患の炎症性状態に陽性の影響を与える物質を同定するための方法

Country Status (6)

Country Link
US (1) US20020150958A1 (https=)
EP (1) EP1346228A2 (https=)
JP (1) JP2004516038A (https=)
CA (1) CA2430610A1 (https=)
MX (1) MXPA03005325A (https=)
WO (1) WO2002052270A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021360A1 (en) * 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
AU2002321229A1 (en) * 2001-08-06 2003-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying anti-inflammatory drugs
WO2004070058A1 (en) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of copd
US20070037156A1 (en) * 2003-08-11 2007-02-15 Lovelace Respiratory Research Institute Metalloproteinase gene polymorphism in copd
WO2007044622A1 (en) 2005-10-07 2007-04-19 Yale University Use of mif and mif pathway agonists
FR2904001A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de la udp-glucose ceramide glucosyltransferase dans le traitement de l'acne ou de l'hyperkeratinisation
CA2893249A1 (en) * 2012-12-07 2014-06-12 Baxter International Inc. Anti-mif antibody cell migration assay

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
WO2001032606A1 (en) * 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity

Similar Documents

Publication Publication Date Title
Bowdish The aging lung: is lung health good health for older adults?
Friedman Hepatic fibrosis
Niimi et al. Nature of airway inflammation and remodeling in chronic cough
Loukides et al. Exhaled H2O2 in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease
Bethke et al. Dose‐proportional intraindividual single‐and repeated‐dose pharmacokinetics of roflumilast, an oral, once‐daily phosphodiesterase 4 inhibitor
Miyaoka et al. Clinical evaluation of circulating interleukin-6 and interleukin-10 levels after surgery-induced inflammation
PT1165110E (pt) Antagonistas de hmg1 para tratamento de condicoes inflamatorias
Zhang et al. Tissue and BAL based biomarkers in asthma
Fujita et al. Serum C-reactive protein levels in postmortem blood—an analysis with special reference to the cause of death and survival time
RU2008145510A (ru) Композиции и способы диагностики и лечения астмы или других аллергических или воспалительных заболеваний
NZ601815A (en) Compositions and methods for treating and diagnosing asthma
RU2009145695A (ru) Способы выявления сердечных нарушений
Molnár et al. Assessment of heat provocation tests on the human gingiva: the effect of periodontal disease and smoking
Kang et al. Neuroprotective effects of magnesium-sulfate on ischemic injury mediated by modulating the release of glutamate and reduced of hyperreperfusion
Johnson et al. Airway smooth muscle and fibroblasts in the pathogenesis of asthma
Kario et al. The influence of work-and home-related stress on the levels and diurnal variation of ambulatory blood pressure and neurohumoral factors in employed women
Stelmach et al. Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis
Ge et al. Differential deposition of fibronectin by asthmatic bronchial epithelial cells
JP2004516038A5 (https=)
Ebina Pathognomonic remodeling of blood and lymphatic capillaries in idiopathic pulmonary fibrosis
Song et al. CTRP3 alleviates myocardial ischemia/reperfusion injury in mice through activating LAMP1/JIP2/JNK pathway
Nakaya et al. Noninvasive system for evaluating allergen-induced nasal hypersensitivity in murine allergic rhinitis
Mitsunobu et al. Enhanced production of leukotrienes by peripheral leukocytes and specific IgE antibodies in patients with chronic obstructive pulmonary disease
RU2008116567A (ru) Биомаркеры
JP2012520446A5 (https=)